Warfarin therapy
231 results
1 - 100
Warfarin therapy - Essentials
- Indications for warfarin therapy
- Complications
- References
- Contraindications to warfarin therapy
- Initiation and intensity of warfarin therapy
- INR determinations
- Interactions
- Duration of the treatment
- Pregnancy and breastfeeding
- Temporary reduction of warfarin dose; bridging therapy
- Thrombosis despite warfarin therapy
Don't add aspirin to warfarin therapy except with mechanical heart valve- Discontinuing warfarin therapy indefinitely after GI bleeding assoc with worse outcomes
- Warfarin or antiplatelet therapy for stroke prevention in patients with non-valvular atrial fibrillation
- Continued warfarin better than bridging therapy for pacemaker or defibrillator surgery (BRUISE CONTROL)
- Antithrombotic agents in primary health care
- NOAC versus warfarin post‐PCI in atrial fibrillation
- Indications for and implementation of anticoagulant therapy in atrial fibrillation
- Benefits to resuming warfarin in patients with atrial fibrillation after intracranial bleeds
- Warfarin superior to antiplatelet treatment for A Fib
- Tinzaparin no better than warfarin in preventing recurrent VTE in adults with cancer
- Warfarin can safely be held for the short term
- 6 months of warfarin after aortic valve replacement reduces risk of CV death
- Continuing warfarin for 18 months after unprovoked PE reduces risk of recurrent VTE
- Warfarin: damned if you do, damned if you don't
Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter: Cochrane systematic review- Vitamins
- Bleeding risk with warfarin high among elderly, especially older than 80
- Clinically significant bleeding occurs in 3.8% per year of pts aged 65+ years using warfarin
- Many patients using warfarin also take aspirin
- Warfarin initiation nomograms for venous thromboembolism: Cochrane systematic review
- Dual therapy with dabigatran and clopidogrel preferred after PCI for patients with AF (RE-DUAL PCI)
- Heart valve operation: patient follow-up and complications
- Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
- Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks: Cochrane systematic review
- NOACs preferred over warfarin for nonvalvular atrial fibrillation in patients also taking low-dose aspirin
- Antiplatelet versus anticoagulation treatment for people with heart failure in sinus rhythm
- More harm than good with bridge therapy in low-risk VTE patients
- Genetic information does not add benefit to a clinical algorithm for warfarin management
- Dabigatran reduces risk of stroke and embolism in patients with AF
- Closure of PFO similar to medical therapy for cryptogenic stroke or TIA
- Extended anticoagulation may be helpul for patients with unprovoked VTE or PE
- Optimal loading dose of warfarin for the initiation of oral anticoagulation
- Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease
- Genotype-guided perioperative warfarin dosing may not be superior to algorithm-guided dosing
- Mitral regurgitation
- Non‐vitamin K antagonist oral anticoagulants (NOACs) after transcatheter aortic valve replacement (TAVR): a network meta‐analysis
- Anticoagulation for heart failure in sinus rhythm
- Vitamin K for improved anticoagulation control in patients receiving warfarin
- Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks: Cochrane systematic review
- Percutaneous left atrial appendage closure reduces AF stroke risk
- Rivaroxaban + clopidogrel causes somewhat less bleeding than triple therapy in patients with AF undergoing PCI